Strong Q2 organic growth of 6%, significant R&DS bookings increase of 19.3%, substantial backlog of $34.2 billion, and rapid AI adoption across 90 use cases with broad pharma customer adoption demonstrate accelerating business momentum and competitive differentiation.
IQVIA is mentioned only in a secondary headline regarding a collaboration with Medera but no details are provided in the main article content. Insufficient information to determine sentiment impact.
Company reported record Q2 bookings of $3.15 billion, 8.7% revenue growth, 12.1% adjusted EPS growth, and raised full-year guidance. CEO's insider sale is attributed to expiring rights rather than negative outlook, and he maintains substantial long-term holdings of 1.4 million shares, demonstrating confidence in the company's prospects.
IQVIA is mentioned as the parent company that established KunTuo and provides its quality management system. While the partnership is positive for KunTuo, there is no direct impact or strategic initiative attributed to IQVIA itself in this announcement.
Articles that tag IQV but are mainly about other companies.
Listed as a prominent participant in the competitive landscape with established technology and clinical analytics platforms. Benefits from strong market growth projections and increasing pharmaceutical industry adoption of AI solutions.
Key company profiled in a rapidly expanding market driven by demand for clinical research analytics, real-world evidence, and data-driven healthcare solutions across Europe.
Featured as a key player in the market and cited for data showing 38% growth in global cell and gene therapy spending ($5.9B in 2023), indicating strong demand for specialized CRO services.
Referenced as a comparable life-sciences technology company with 8.7% revenue growth in Q2 2026, providing industry context but not directly related to the article's focus on Veeva.
IQVIA reported solid results with 8.7% revenue growth and 12.1% EPS growth year-over-year. The company has a Zacks Rank #3 (Hold) with stable consensus estimates over the past 30 days and a VGM Score of C, indicating a balanced but unremarkable outlook.
Listed among key market players in the eClinical Solutions sector, which is benefiting from rising pharmaceutical R&D investment and increased adoption of digital trial management solutions.
Launched One Home for Sites platform in June 2024 supporting decentralized and hybrid trials, positioning the company at the forefront of technology-driven market trends.
Innovated safety surveillance analytics platform leveraging AI and real-world data in 2025, demonstrating competitive advancement in signal detection capabilities.
Listed among top market players in the decentralized clinical trials sector, which is experiencing significant market expansion and adoption.
Despite falling 28.6% YTD, company reported strong Q1 2026 results with EPS of $2.90 (above $2.83 expectations) and raised full-year guidance. Stock trades 25-85% below fair value with analyst target of $229.60 vs current $157, suggesting significant upside.
Mentioned as the data provider for prescription information; no direct impact on the company's operations or outlook, serving only as a source of market intelligence.
Actively innovating with the launch of 'One Home for Sites' platform in June 2024, demonstrating commitment to streamlining clinical trial processes and reducing administrative burdens
Listed as a key industry player in the rapidly growing AI clinical trial feasibility tool market, which is expanding at 27% CAGR with strong demand drivers.
Named among major players in a rapidly growing market driven by AI adoption and cloud-based solutions.
Identified as a leading company in the sector with strong market position in the growing AI clinical trial solutions market
Featured as a key player in the rapidly growing clinical trials market, benefiting from trends in AI adoption and decentralized trial expansion.
Listed as a prominent player in the drug development services market, positioned to benefit from the projected 12.4% CAGR growth through 2030 and increasing outsourcing of drug development services.
IQVIA is acquiring Charles River's European Discovery Services assets for approximately $145 million, expanding its discovery services capabilities and portfolio of assets that have enabled over 100 molecules to enter clinical trials.
Listed as a major player in the rapidly growing pharmacovigilance market with strong market expansion driven by regulatory requirements and increased demand for drug safety solutions.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
